A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen
A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells.
PURPOSE: This phase II trial is studying how well tamoxifen citrate works in patients with metastatic or recurrent breast cancer.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Patients receive oral tamoxifen citrate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicities.
Blood, plasma, and tissue samples are collected periodically for laboratory studies.
After completion of study therapy, patients are followed up every 3-6 months for 5 years.
Inclusion Criteria:
Histologically confirmed adenocarcinoma of the breast
Estrogen-receptor and/or progesterone-receptor positive disease
Measurable or non-measurable disease
ECOG performance status 0-2
History of central nervous system (CNS) metastasis allowed provided it has been treated (surgery, radiotherapy, or radiosurgery) within the past 4 weeks and does not require medications to control symptoms
Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases present)
Negative pregnancy test
Fertile patients must use effective nonhormonal contraception
Disease-free of prior invasive malignancies for ≥ 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Prior chemotherapy, trastuzumab, or bevacizumab in the adjuvant setting allowed provided it has been completed ≥ 4 weeks before study therapy; other prior non-hormonal investigational agents in the adjuvant setting must have been completed at least 4 weeks prior to study registration and should be discussed with the study PI
Prior tamoxifen as adjuvant treatment is allowed as long as the patient did not have disease relapse or progression while on adjuvant tamoxifen or within 4 weeks of last dose
Treatment in the advanced setting must have been completed at least 2 weeks prior to study initiation
Prior aromatase inhibitors (e.g., anastrozole, letrozole, exemestane, aminoglutethamide) are allowed in the adjuvant or metastatic setting
At least 2 weeks since prior and no concurrent medications that are strong to moderate inhibitors of CYP2D6 and may alter tamoxifen citrate metabolism including, but not limited to, any of the following:
Concurrent radiotherapy to painful sites of bone disease or areas of impending fractures allowed provided the following criteria are met:
Exclusion Criteria:
Pregnant or nursing
Concurrent chemotherapy
Leptomeningeal disease
Non-protocol concurrent hormonal therapy
Medical or psychiatric conditions that would interfere with protocol compliance, the ability to provide informed consent, assessment of response, or anticipated toxicities
Prior tamoxifen for advanced disease
More than 2 lines of non-hormonal treatment in the locally advanced or metastatic setting, including trastuzumab (Herceptin), bevacizumab, or other biologics
Starting bisphosphonate therapy while receiving treatment on this study
Fort Smith, Arkansas 72903, United States
Marysville, California 95901, United States
Grand Junction, Colorado 81502, United States
Washington D.C., District of Columbia 20007, United States
Washington D.C., District of Columbia 20010, United States
Savannah, Georgia 31405, United States
Beech Grove, Indiana 46107, United States
La Porte, Indiana 46350, United States
Des Moines, Iowa 50309, United States
Des Moines, Iowa 50314, United States
Wichita, Kansas 67214, United States
Baltimore, Maryland 21201, United States
Baltimore, Maryland 21231-2410, United States
Minneapolis, Minnesota 55407, United States
Robbinsdale, Minnesota 55422-2900, United States
Billings, Montana 59102, United States
Missoula, Montana 59807, United States
Marlton, New Jersey 08053, United States
Toms River, New Jersey 08755, United States
Voorhees Township, New Jersey 08043, United States
Voorhees Township, New Jersey 08043, United States
The Bronx, New York 10461, United States
Wright-Patterson Air Force Base, Ohio 45433-5529, United States
Hershey, Pennsylvania 17033-0850, United States
Philadelphia, Pennsylvania 19107-5541, United States
Sioux Falls, South Dakota 57117-5039, United States
Dallas, Texas 75390, United States
Seattle, Washington 98122-4307, United States
Seattle, Washington 98195, United States
Charleston, West Virginia 25304, United States
Green Bay, Wisconsin 54301-3526, United States
Green Bay, Wisconsin 54311, United States
Manitowoc, Wisconsin 54221-1450, United States
Summit, Wisconsin 53066, United States
Wausau, Wisconsin 54401, United States